Skip to main content

Table 7 AEs in all patients with C1-INH-HAE

From: Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

  Underweight BMI (n = 18) Normal BMI (n = 210) Overweight BMI (n = 162) Obese BMI (n = 73)
No. of patients, no. of events 3, 3 48, 101 33, 91 19, 53
AEs related to icatibant (no. of patients, no. of events)a 0, 0 7, 24 6, 29 2, 5
 General disorders and administration site conditions 0, 0 5, 9 3, 11 1, 1
 Vascular disorders 0, 0 3, 5 3, 4 1, 3
 Skin and subcutaneous tissue disorders 0, 0 0, 0 2, 2 1, 1
 Gastrointestinal disorders 0, 0 2, 2 1, 3 0, 0
 Nervous system disorders 0, 0 1, 1 1, 2 0, 0
 Investigations 0, 0 2, 5 0, 0 0, 0
Serious AEs (no. of patients, no. of events) 0, 0 20, 28 16, 32 11, 30
Serious AEs related to icatibant and (no. of patients, no. of events)b 0, 0 0, 0 2, 3 0, 0
 Skin and subcutaneous tissue disorders     
  Angioedema 0, 0 0, 0 1, 1 0, 0
 Gastrointestinal disorders     
  Gastritis 0, 0 0, 0 1, 1 0, 0
  Reflux esophagitis 0, 0 0, 0 1, 1 0, 0
  1. A missing relationship to icatibant was considered related to icatibant
  2. AE adverse event; BMI body mass index; C1-INH-HAE hereditary angioedema due to C1-inhibitor deficiency; n = number of patients
  3. aListed by medical dictionary for regulatory activities system organ class. Only AEs that were reported in ≥ 2 patients are presented
  4. bListed by medical dictionary for regulatory activities system organ class and preferred term